On September 19, 2025, Zonhonbio's original Category 1 therapeutic biological new drug ZHB110 Sublingual Tablets, which possesses complete independent intellectual property rights both domestically and internationally, received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. The newly approved indication is for the desensitization treatment of Artemisia pollen-induced allergic rhinitis or rhinoconjunctivitis (with or without allergic asthma) in children aged 3–17 years.